Cadence Pharmaceuticals Completes $49.3 Million Registered Direc... ( SAN DIEGO Feb. 20 /- Cadence Phar...)

Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering

Date:2/20/2008

SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it completed its previously announced registered direct offering of approximately 9.2 million shares of common stock at a price of $5.34 per share, for gross proceeds of $49.3 million.

"The proceeds from the offering will enable us to continue to advance the clinical development programs for our two products candidates, Acetavance(TM) for the treatment of acute pain and fever, and Omigard(TM) for the prevention of catheter-related infections," stated Ted Schroeder, President and Chief Executive Officer of Cadence. "We believe that we now have sufficient capital to advance these two product candidates through to NDA submissions, currently anticipated in the first half of 2009."

In addition to significant participation from existing investors Domain Associates, Frazier Healthcare Ventures and Versant Ventures, as well as from certain executive officers and directors of Cadence, other investors participating in this financing included, among others, Bay City Capital.

All of the shares of Cadence common stock were issued pursuant to an effective registration statement previously filed with the U.S. Securities and Exchange Commission. The offering and sale of these securities were made only by means of a prospectus supplement and accompanying prospectus. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/20/2013)... 2013 , Collaboration with ... (ARS) in treatment of mastitis , ... Trials to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will ... Research Service (ARS) to develop and trial products targeting ...

(Date:5/20/2013)... 20, 2013 Today, at the American Psychiatric ... , James McGough , M.D., M.S., ... Semel Institute for Neuroscience and Human Behavior and ... the University of California Los Angeles (UCLA), and director ... Psychopharmacology and ADHD at UCLA, presented the results of ...

(Date:5/20/2013)... 2013 With bed bugs' presence come problems ... bed bugs need to be eliminated, one must make sure ... person's health. And so to help bed bug sufferers get ... rid of bed bugs without using harmful pesticides. In ... it called Bed Bug Bully. , According to My Cleaning ...

(Date:5/20/2013)... 20, 2013 Rhythm announced today the results ... the company,s novel ghrelin agonist for the treatment of ... demonstrated that RM-131 significantly accelerates early gastric emptying and ... patients with diabetic gastroparesis. The findings were presented at ... Orlando and recently published in Clinical ...

Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4 Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5 New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2 Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2 Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3

[0] Phosphagenics Signs Research Agreement with the Agricultural Research Service [0] Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS)[0] New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products [0] Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes

... Sutro Biopharma, a biopharmaceutical company developing novel ... today announced that the company,s proprietary biochemical protein ... of novel protein therapeutics will be presented at ... Trevor Hallam, Ph.D., chief scientific officer of Sutro, ...

... Dynamics International (CDI) today announced that it was ... Street Journal Technology Innovation Awards. ... determined by a panel of independent judges who evaluated significant ... award in 16 categories. Of these, the panel chose 35 ...

... 2011 Reportlinker.com announces that a ... in its catalogue: ... and Market Forecasts to 2018 ... Influenza Vaccines Therapeutics - Pipeline ...

Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin Cellular Dynamics International's (CDI) Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018

(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...

(Date:5/19/2013)... engineered a strain of electricity-producing bacteria that can grow ... carbon dioxide as its sole source of carbon. ... findings at the 113th General Meeting of the American ... of current production solely on hydrogen," says Amit Kumar, ... co-authors are part of the Lovley Lab Group at ...

(Date:5/18/2013)... FL (May 18, 2013) Research presented at ... managing digestive health through diet and lifestyle. ... plagued by reduced muscle strength, fatigue and poor ... when patients are in remission. A randomized, double ... that vitamin D supplementation corresponded to significant relief ...

Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2 Research examines new methods for managing digestive health 2 Research examines new methods for managing digestive health 3

[0] Germ-fighting vaccine system makes great strides in delivery [0] Bacteria use hydrogen, carbon dioxide to produce electricity [0] Research examines new methods for managing digestive health

... of a pinhead, but the latest research from the University ... For the first time, researchers from the University,s Discipline of ... moving objects. It appears that insect brain cells have ... landing on a flower or reach a food source. This ...

... CLEMSON, S.C. With a new twist on an ... to store "waste" energy underground to cut heating and cooling ... Molz have received a $991,000 grant from the U.S. Department ... system that can be used as a model for energy ...

... to better understand how the brain chooses between competing behaviors ... School and New York University have isolated two genes in ... mediate the need to sleep and the need to eat. ... Current Biology , offers insights that may be used to ...

Cached Biology News:Tiny insect brains capable of huge feats 2 Clemson engineers to create model underground energy-storage facility 2 Clemson engineers to create model underground energy-storage facility 3 Biologists identify genes regulating sleeping and feeding 2

Tiny insect brains capable of huge feats Clemson engineers to create model underground energy-storage facility Biologists identify genes regulating sleeping and feeding

... white. The extinction coefficient , E(1%) at ... phosphate-buffered saline, pH 7.4, containing ... 50% glycerol. Avidin (from egg white) is conjugated ... molecular sieving and is completely ...

... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...

Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...

Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...

Biology Products:

Avidin, FITC conjugated/tagged from Invitrogen Zero Blunt TOPO PCR Cloning Kit for Sequencing with One Shot TOP10 Electrocomp E. coli from Invitrogen Caspase-6 Inhibitor Z-VEID-FMK from BioVision Human CCL21 / 6Ckine, Unconjugated, Fc Chimera from R&D Systems